Roche Advances MS Drug Fenebrutinib to Regulatory Review Amid Safety Concerns
The Swiss drugmaker Roche has presented promising data for its experimental multiple sclerosis drug, fenebrutinib, positioning itself to seek regulatory approval for a treatment aimed at reducing relapse rates and slowing the progression of disability associated with the disease. While the results from three late-stage trials indicate the drug’s efficacy, analysts are raising alarms about…









